Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Verana Health launches Qdata anti-VEGF market tracker for in-depth market analysis

By Brian Buntz | April 7, 2023

Verana HealthDigital health company Verana Health (San Francisco) has unveiled the Qdata anti-VEGF market tracker. It is their first market tracking Data as a Service (DaaS) product.

Excessive amounts of vascular endothelial growth factor (VEGF) can cause abnormal blood vessel growth in the eyes, which, when untreated, can result in vision loss in patients with retinal diseases. Consequently, anti-VEGF therapies help preserve eyesight for patients with conditions such as age-related macular degeneration and diabetic retinopathy.

Qdata anti-VEGF market tracker supports brand-level analysis

The Qdata anti-VEGF market tracker enables comprehensive brand-level analysis. It also provides direct access to real-world data, according to Sujay Jadhav, Verana Health’s CEO. The service offers accurate and timely insights into product performance and market dynamics.

Sujay Jadhav

Sujay Jadhav

Real-world data is drawn from the American Academy of Ophthalmology’s IRIS Registry (Intelligent Research in Sight). The market tracker is offered in AWS Data Exchange. This service enables Amazon Web Services (AWS) customers to use third-party data in the cloud.

The tracker is built on a secure cloud infrastructure. It has customizable market dashboards and features a highly intuitive visualization layer. This allows life sciences companies to customize data reporting and monitor market uptake.

The Qdata anti-VEGF market tracker enables users to access data that is roughly one-month old. Jadhav said, “Historically, people have used claims data as a source to understand anti-VEGF usage patterns.” That practice typically resulted in a two- to three-month delay in reviewing anti-VEGF medication use in a given month.

The tracker offers granular market segmentation at the brand level. This enables drug companies to analyze the performance of specific anti-VEGF products.

Comprehensive de-identified data

The Qdata anti-VEGF market tracker draws data from more than 850,000 patients and 4.8 million anti-VEGF injections. It provides “a comprehensive module of de-identified structured and unstructured electronic health record (EHR) data, curated securely and compliantly for insight delivery,” said Jadhav. With data from over 2,300 clinicians across six key indications, he emphasized the service’s wide-ranging data set. He stated that it “ensures reliable and accurate insights.”

Jadhav said the Qdata anti-VEGF market tracker can inform commercial planning and sales forecasting. It provides an overview of market share by drug. “The tracker supports longitudinal data and real-world evidence, which can inform commercial strategies for companies selling anti-VEGF agents,” according to Jadhav. It also offers information about medication switching. He added, “Life sciences companies can customize data reporting and monitor market uptake for products. They can adapt to the specific needs and goals in a highly competitive market.”

The IRIS Registry, launched in 2014, was the first comprehensive eye disease clinical registry in the U.S. It supports research, quality improvement, and patient care initiatives. The registry is a collaborative project between the American Academy of Ophthalmology and Verana Health. It is one of the largest specialty society clinical data registries in medicine. The IRIS Registry contains data from millions of patients and various clinical settings. This contributes to a better understanding of eye diseases and treatment outcomes. As of 2023, the registry includes data on 2.2 million patients who received anti-VEGF injections. This provides a robust dataset for the Qdata anti-VEGF market tracker. It enables granular analysis of the anti-VEGF market and its trends.


Filed Under: Drug Discovery and Development, Ophthalmology
Tagged With: anti-VEGF therapies, DaaS, data as a service, eye conditions, IRIS Registry, market analysis, Qdata Anti-VEGF Market Tracker, real-world data, retinal diseases, VEGF, Verana Health
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

AMD
Promising phase 2 data suggests new drug could save sight in dry AMD
Structure of human eye. In side view.
Gene therapy yields 100x vision average improvement, with a few reaching 10,000x
Ozempic
JAMA study suggests link between semaglutide and eye disorder
Retina slice
Molecular photoswitches: Illuminating the future of inherited retinal disease treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE